Antiviral peptides against dengue virus

Lee, Michelle Felicia * and Anasir, Mohd Ishtiaq and Poh, Chit Laa * (2022) Antiviral peptides against dengue virus. In: Viral infections and antiviral therapies. Academic Press, London, pp. 581-610. ISBN 9780323972420

Full text not available from this repository. (Request a copy)
Official URL:


Dengue virus (DENV) poses a continuous threat to the public health of the global community with over 390 million infections and 25,000 deaths annually. The efficacy of the only licensed dengue vaccine, Dengvaxia, against all four DENV serotypes is less than desirable in real-world setting. In addition, there is a lack of clinically approved antiviral drugs against DENV. This drives an urgent need for the development of novel dengue therapeutics. Technological advancements in recent years have paved the way towards initiating an interest in the development of peptide drugs by the pharmaceutical industry. This chapter highlights the current status of the development of antiviral peptides targeting DENV, strategies that were utilized to design antiviral peptides, interactions that were identified between antiviral peptides and DENV host cell receptors or enzymes, advantages and disadvantages of antiviral peptides, as well as potential ways to overcome their limitations.

Item Type: Book Section
Uncontrolled Keywords: dengue virus; peptides; antivirals; chemical modifications; nanomaterials
Subjects: R Medicine > RA Public aspects of medicine
Divisions: Others > Non Sunway Academics
Sunway University > School of Medical and Life Sciences [formerly School of Healthcare and Medical Sciences until 2020] > Centre for Virus and Vaccine Research [dissolved]
Depositing User: Ms Yong Yee Chan
Related URLs:
Date Deposited: 20 Mar 2023 04:06
Last Modified: 20 Mar 2023 04:06

Actions (login required)

View Item View Item